Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis, Autoimmune, and Ocular Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ROCK2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ROCK2 Kinase Domain (Active) / Full-Length Recombinant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed. | View ROCK2 Products |
| Mutant Panel | ROCK2 Resistance Mutants (Gatekeeper, Activation Loop). For selectivity profiling and resistance mechanism studies. | View ROCK2 Products |
| Gene Delivery | ROCK2 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines (pMLC, stress fiber assays). | View ROCK2 Products |
| Validator | ROCK2 siRNA Set. For knockdown verification and pathway analysis. | View ROCK2 Products |
| Benchmark Ab | Anti-ROCK2 Monoclonal Antibody (Research Grade). Validated for Western Blot, IF, and IHC. | View ROCK2 Products |
| Related Target A | ROCK1. Paralog kinase; essential selectivity counter-screen to avoid cardiovascular liabilities. | View ROCK1 Products |
| Related Target B | STAT3. Downstream transcription factor regulated by ROCK2; crucial for Th17/Treg balance readouts. | View STAT3 Products |
| Related Target C | LIMK1. Downstream effector in actin dynamics; pathway validation and phenotypic readout control. | View LIMK1 Products |
| Related Target D | RHOA. Upstream regulatory partner for activation assays. | View RHOA Products |
Critical Assay Challenges & TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ROCK1 vs. ROCK2 Subtype Selectivity | High-purity (>95%) homologous ROCK1 and ROCK2 kinase domains strictly verified by mass spectrometry. |
| Intracellular Kinase Enzymatic Stability | Expression optimized for native-like folding; Sequence Verified sequences ensure accurate structural presentation. |
| Lack of Standardized Controls | High-affinity recombinant Benchmark Antibodies included for reproducible assay baselines. |
| Target Engagement False Positives | Highly specific siRNA included for cellular knockdown and phenotype specificity checks. |
| Resistance Profiling | Mutant ROCK2 kinases (Gatekeeper, Activation Loop) available for secondary screening and resistance mechanism studies. |
Global Clinical Landscape & Future Outlook
The race for ROCK2-selective therapeutics is intensifying following the approval of belumosudil (REZUROCK) for chronic GVHD. Major players are shifting focus from pan-ROCK inhibitors to isoform-selective modulators to circumvent cardiovascular liabilities associated with ROCK1 inhibition. The next wave of R&D targets broader indications including idiopathic pulmonary fibrosis (IPF), psoriasis, and neurodegenerative disorders. Emerging modalities include PROTAC degraders for enhanced specificity and CNS-penetrant inhibitors for neurological applications. Strict selectivity against ROCK1 remains the central developmental challenge.
Molecular Characteristics and Key Mutations
ROCK2 (UniProt O75116) comprises three annotated functional domains: the Protein kinase domain, the AGC-kinase C-terminal domain, and the REM-1 domain. These domains regulate its kinase activity and substrate recruitment. Several single nucleotide variants have been cataloged in dbSNP: rs2230774, rs35768389, and rs34945852. These mutations may influence kinase function or drug sensitivity and serve as important markers for resistance profiling.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Selective) | Sanofi, Kadmon, Redx Pharma | cGVHD, Fibrosis, Autoimmune | Selectivity Assay (Need High-Purity Homolog Proteins ROCK1/ROCK2) |
| Targeted Protein Degrader (PROTAC) | Emerging Biotechs | Refractory Fibrosis / Oncology | Ternary Complex Formation (Need Specific Truncations & Ligase controls) |
| Pan-ROCK Inhibitor | Kowa, Aerie Pharmaceuticals | Glaucoma, Ocular Hypertension | Enzymatic Inhibition Assay (Need strictly quality-controlled Kinase Domains) |
Live ROCK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: